Abstract
This paper reports on a double blind trial of the effect of buspirone, 15 mg per day, on cigarette withdrawal symptoms and ability of smokers to maintain abstinence during treatment. A total of 61 smokers were randomly assigned to active or placebo conditions. They were maintained on their drug for 2 weeks prior to attempting abstinence and then for a further 4 weeks of abstinence. Subjects attended weekly group sessions of a psychological treatment programme. There was no evidence that the side effects in the active drug group were worse than those in the placebo group. Although there was no significant difference between active and placebo conditions on withdrawal symptoms, smokers in the active drug condition were more than twice as likely to maintain abstinence for the duration of the study than those in the placebo condition (47% versus 16%, chi square = 5.3,P<0.025). The results provide preliminary evidence for short-term efficacy of buspirone as an aid to smoking cessation at a low dose. They also provide evidence of a dissociation between withdrawal symptoms and successful abstinence.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Balfour D (1991) The influence of stress on psychopharmacological responses to nicotine. Br J Addict (in press)
Fagerstrom KO (1988) Efficacy of nicotine chewing gum: a review. In: Pomerleau O, Pomerleau C (eds) Nicotine replacement: a critical evaluation. Alan Liss, New York, pp 109–128
Franks P, Harp J, Bell B (1989) Randomized, controlled trial of clonidine for smoking cessation in a primary care setting. JAMA 262:3011–3013
Grunberg NE, Baum A (1985) Biological commonalities of stress and substance abuse. In: Shiffman S, Wills TA (eds) Coping and substance abuse. Academic Press, Orlando, pp 25–61
Hajek P (1989) Withdrawal oriented therapy for smokers. Br J Addict 84:591–599
Hajek P, Belcher M, Stapleton J (1985) Enhancing the impact of groups: evaluation of two groups formats in treatment of smoking. Br J Clin Psychol 24:289–294
Hughes JR, Higgins ST, Hatsukami D (1990) Effects of abstinence from tobacco. In: Kozlowski L, Annis H, Cappell H et al. (eds) Research advances in alcohol and drug problems. Plenum Press, New York
Kranzler HR, Meyer RE (1989) An open trial of buspirone in alcoholics. J Clin Psychopharmacol 9:379–380
Lader M (1987) Assessing the potential for buspirone dependence or abuse and effects of its withdrawal. Am J Med 82 [suppl. 5A]:20–26
Newton RE, Marunycz JD, Alderidge MT, Napoliello MJ (1986) Review of the side-effect profile of Buspirone. Am J Med 80:17–21
Rickels K, Schweitzer E, Caanalosi I, Case G, Chung H (1988) Long term treatment of anxiety and risk of withdrawal: prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 45:444–450
Taylor DP (1988) Buspirone: a new approach to the treatment of anxiety. Fed Am Soc Exp Biol J 2:2445–2452
United States Department of Health and Human Services (1988) The health consequences of smoking. Nicotine addiction: a report of the surgeon general
West R (1989) Nicotine: a dependence-producing substance. In: Pomerleau O, Pomerleau C (eds) Nicotine replacement in the treatment of smoking: a critical evaluation. Alan Liss, New York
West R, Hajek P, Belcher M (1989) Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking. Psychological Medicine 19:981–985
West R, Russell M (1985) Pre-abstinence smoke intake and smoking motivation as predictors of severity of cigarette withdrawal symptoms. Psychopharmacology 87:334–336
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
West, R., Hajek, P. & McNeill, A. Effect of buspirone on cigarette withdrawal symptoms and short-term abstinence rates in a smokers clinic. Psychopharmacology 104, 91–96 (1991). https://doi.org/10.1007/BF02244560
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02244560